We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Office of Inspector General (OIG) within the Department of Health and Human Services has called for the increased use of biosimilars to reduce spending by the federal government’s Medicare Part D prescription drug program. Read More
Bayer’s Kerendia (finerenone) reduced the risk of cardiovascular and kidney disease events in patients with type 2 diabetes and chronic kidney disease, being especially effective in those with atherosclerotic cardiovascular disease (ASCVD). Read More
Today, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) will attempt to grapple with the problem of SARS-CoV-2’s vexing ability to escape vaccine coverage. Read More
Ocrevus (ocrelizumab), Roche’s FDA-approved multiple sclerosis (MS) antibody, demonstrated hints of disease modification and cognitive benefit in phase 3b data that will be presented at the annual meeting of the American Academy of Neurology (AAN). Read More
Bristol Myers Squibbs’ (BMS) investigational drug mavacamten, which reduces cardiac muscle contractility, improved both functional and biomarker outcomes in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), a form of progressive heart failure. Read More
HHS and the FDA have expanded the list of states where GlaxoSmithKline’s and Vir Biotechnology’s COVID-19 monoclonal antibody, sotrovimab, may not be used due to concerns about the treatment’s efficacy against the Omicron subvariant BA.2. Read More
A trial in West Virginia before Judge Derek Swope got under way yesterday against Johnson & Johnson (J&J), Teva Pharmaceuticals and AbbVie for their alleged role in facilitating the state’s opioid crisis. Read More
The FDA has approved Kite’s Yescarta (axicabtagene ciloleucel) drug for a new indication — initial treatment for patients with relapsed or refractory large B-cell lymphoma (LBCL), which its parents company Gilead said is the first chimeric antigen receptor (CAR) T-cell therapy to have done so. Read More